DEUTERIUM-ENRICHED RISPERIDONE
The present application describes deuterium-enriched risperidone, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
1 . (canceled)
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . (canceled)
7 . (canceled)
8 . A deuterium-enriched compound, wherein the compound is selected from:
or a pharmaceutically acceptable salt, wherein when one of R 1 -R 27 is present, it is selected from H or D.
9 . (canceled)
10 . (canceled)
11 . (canceled)
12 . (canceled)
13 . (canceled)
14 . (canceled)
15 . (canceled)
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof.
22 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-8 and R 12-27 are selected from H and D.
23 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-15 and R 25-27 are selected from H and D.
24 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-24 are selected from H and D.
25 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-24 are selected from H and D.
26 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof.
27 . A deuterium-enriched compound, wherein the compound is:
or a pharmaceutically acceptable salt thereof.
28 . A pharmaceutical composition, comprising: a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound selected from:
or a pharmaceutically acceptable salt form thereof.
29 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt.
30 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-8 and R 12-27 are selected from H and D.
31 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-15 and R 25-27 are selected from H and D.
32 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-24 are selected from H and D.
33 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
34 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
35 . The pharmaceutical composition of claim 28 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
36 . A method for treating schizophrenia comprising: administering, to a patient in need thereof, a therapeutically effective amount of a compound selected from:
or a pharmaceutically acceptable salt form thereof.
37 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt.
38 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-8 and R 12-27 are selected from H and D.
39 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-15 and R 25-27 are selected from H and D.
40 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof, wherein R 1-24 are selected from H and D.
41 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
42 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.
43 . The method of claim 36 , wherein the compound is:
or a pharmaceutically acceptable salt thereof.